Vivek Subbiah: What is Missing to Fully Harness Precision Medicine and Transform Cancer Care
Vivek Subbiah, Chief of Early-Phase Drug Development at Sarah Cannon Research Institute, shared a post on LinkedIn he and colleagues co-authored, published in Nature Medicine.
“Delighted to share our paper published in Nature Medicine ‘Cancer treatment paradigms in the Precision Medicine era.’
To fully harness precision medicine and transform cancer care for the better will require a strategic shift to highly personalized interventions that embrace innovation and adaptability.”
Title: Cancer treatment paradigms in the precision medicine era
Authors: Vivek Subbiah, Giuseppe Curigliano, Jason K. Sicklick, Shumei Kato, Kjetil Tasken, Arielle Medford, Damian T. Rieke, Hui-Zi Chen, Adam Wahida, Lars Buschhorn, Denis Horgan, Razelle Kurzrock
Read The Full Article at Nature Medicine.
More posts featuring Vivek Subbiah on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023